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Abstract
Background: The purpose was to determine the professionally-guided and self-guided medication and
supplement use for joint symptom management among patients with knee and/or hip osteoarthritis (OA) in an
urban hospital-based outpatient orthopedic practice.
Methods: The study design was cross-sectional. Patients diagnosed by radiographs and clinical symptoms with
knee and/or hip OA were recruited from an inner-city hospital-based outpatient orthopaedic office. A total of 184
patients were queried for their participation. Four investigator-generated, interview-based questionnaires were
used. Sampling error was ± 7.84%. Logistic regression models and Fisher Exact Tests were performed to determine
factors that may be associated with negative behaviors related to medication or supplement use (e.g., reporting
medication as ineffective, using multiple medications in the same day to manage symptoms). Odds ratios (OR) and
95% confidence intervals (CI) were calculated for significant findings.
Results: Among the 162 participants, a majority reported professionally-guided recommendations and over 40%
reported at least one self-guided intervention. 37 participants reported dual-use during the same day, and among
those,15 reported dual-use at the same time. Among participants taking multiple interventions in the same day,
40.5% reported using prescription and over-the-counter medications. Use of multiple medications or supplements
in one day was more common among participants who reported OA at multiple joints (OR [95% CI] = 2.48 [1.03 to
5.96]) but less common among participants who did not complete high school (OR [95% CI] = 0.26 [0.08 to 0.83]).
Of the 15 participants who reported dual-use at the same time, 11 were professionally-guided, 5 were professional
and self-guided, and 1 was solely self-guided. Overall, 28% of participants reported their intervention as ineffective,
sought an alternative method to achieve symptomatic relief, or were prescribed a stronger medication. Participants
who reported not always taking their medication consistently for 2 weeks were more likely to report their
medication as ineffective (OR [95% CI] = 2.87 [1.19 to 6.92]).
Conclusions: Both professional and self-guided medications and supplements are used by inner city OA patients
to manage their joint symptoms. It is important for clinicians to discuss with these patients how to effectively
manage multiple joint symptoms, the importance of taking medications as prescribed, and what they should if
they believe a treatment is ineffective or their medication runs out.
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Osteoarthritis (OA), the most common form of arthritis,
is a heterogeneous disease characterized by multi-tissue
failure of the synovial joints and an illness defined by
patient reported symptoms (e.g., pain, stiffness) [1].
Symptom management, is important to an individual’s
quality of life and function, and is the primary focus of
current OA treatment [2]. OA symptom management
includes both professionally-guided as well as self-
guided care interventions [3,4]. Self-guided care is
undertaken based on information obtained from profes-
sionals and other personal experiences [3] and has long
been recognized for its importance in chronic disease
management [5]. Self-guided care for OA includes over-
the-counter (OTC) medications, prescription drugs not
used for their prescribed purpose, and dietary supple-
ments that individuals take to ameliorate their symp-
toms [3]. Professionally-guided care typically consists of
prescription and OTC medications, injections, and phy-
sical therapy prescribed by physicians [3].
In the United States, it is not fully understood how
OA patients manage their symptoms with profession-
ally-guided and self-guided pharmacological care strate-
gies. Among patients taking a non-steroidal anti-
inflammatory drug (NSAID) for management of their
joint discomfort (e.g., rheumatoid arthritis, OA, low
back pain), approximately 26% also use other analgesic
medications [6]. Specifically among OA patients, it is
estimated that 70% take a prescription medication and
44 to 70% take an OTC analgesic to control joint symp-
toms [3]. While a high percentage of OA patients take
prescription and/or OTC analgesics, it is unclear how
many OA patients combine medications. In addition,
the pattern of use within the same day and at the same
time is unknown. As the incidence of OA increases, the
use of multiple medications to control for symptoms is
likely to increase as well.
In spite of the guidelines and recommendations that
exist for the management of OA, inappropriate multiple
analgesic medication use among OA patients may repre-
sent an additional burden on a health-care system that
is struggling to adapt to an increasing prevalence of
chronic diseases [7]. In the United Kingdom and United
States, 25 and 54% of patients, respectively, are not
aware of potential drug side effects and do not under-
stand that analgesics can be taken prophylactically or at
the onset of pain [6,8]. Twenty-six and 8% of patients
over medicate with OTC and prescription NSAIDs,
respectively. In the United States it has not been deter-
mined which medications are being combined among
OA patients and if these patients are taking the medica-
tions at the same time, potentially placing their health
at risk (e.g., gastrointestinal toxicity, hepatic complica-
tions, renal complications) [6,8]. The purpose of our
study was to determine the professionally-guided and
self-guided pharmacological and supplement use for
joint symptom management among knee and hip OA
patients in an urban hospital-based outpatient orthope-
dic practice. The outcome of this study is intended to
improve clinical care and education of OA patients.
Methods
Participants
Participants were recruited from Temple University
Hospital’s Department of Orthopedics inner-city outpa-
tient office between December 2009 and March 2011.
The participants were all under the care of one of 3
board-certified orthopedic physicians for knee and/or
hip OA. The OA diagnosis was based on x-ray (Kellg-
ren-Lawrence score ≥ 1) [9] as well as knee or hip clini-
cal symptoms (e.g., pain, stiffness, swelling, impaired
function). Exclusion criteria were any other rheumatic
disease (e.g., rheumatoid arthritis, lupus, gout) or diag-
nosis of complex regional pain syndrome. A total of 184
patients were queried for their participation in the study
of which 22 patients were excluded and/or declined to
participate. Characteristics of those not willing to parti-
cipate are unknown. Institutional Review Board approval
by Temple University’s Institutional Review Board as
well as written informed consent were obtained prior to
data collection.
Research design
The study design was cross-sectional. Four interview-
based questionnaires were used to address the specific
aims and research questions of the study: Demographic
and Health History Questionnaire, Health History Fol-
low-up Questionnaire, Pharmacological and Supplement
Use Assessment Questionnaire, and Pharmacological
and Supplement Use Follow-up Questionnaire (see
Additional file 1). A priority of 8 specific aims with sev-
eral specific research questions were identified and
approached as an exploratory analysis in this study. Pro-
fessionally-guided care was defined as a prescription
medication, OTC medication, or dietary supplement
recommended by a physician. Self-guided care was
defined as any OTC medication, prescription drug not
used for its original purpose, or dietary supplement
taken without the recommendation from a physician.
Instrumentation
Four interview-based questionnaires were used to obtain
information about the participant’s health history and
pharmacological and supplemental use: two initial ques-
tionnaires and two follow-up questionnaires. The ques-
tionnaires were developed by the research team and
reviewed by two statisticians: one specializing in psy-
choeducational assessment research and the other in
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naires were interview based. The questionnaires were an
item-by-item design, where each question could be
scored individually. The interviewer practiced the proce-
dures and data coding on 18 non-study patients with
knee OA prior to starting the study.
Demographic and health history questionnaire
The Demographic and Health History Questionnaire was
used to obtain participant general health as well as knee
and/or hip joint specific information. It consisted of par-
ticipant identity information and questions concerning
his/her demographics, education level, physical activity
level, knee and/or hip injury and treatments (e.g., medi-
cation use), and general medical history. In addition,
each participant was asked to list all medications he/she
was currently taking. The Demographic and Health His-
tory Questionnaire consisted of “yes” or “no”, Likert-type
5-point scale, as well as open- and close-ended questions.
Health history follow-up questionnaire
The Health History Follow-up Questionnaire was used
to discern additional information in follow-up to the
Demographic and Health History Questionnaire. Follow-
up questions were prompted if a participant responded
“yes” to any questions regarding previous injury, surgery,
other arthritic joint, other treatments used for OA, and
sport participation history.
Pharmacological and supplement use assessment
questionnaire
The Pharmacological and Supplement Use Assessment
Questionnaire was used to identify the specific medica-
tions commonly used by the participant as part of his/
her knee and/or hip OA joint symptom management.
Drug categories were: NSAIDs, herbal remedies, nutri-
tional supplements, injections, acetaminophen, pain
relieving medications, and any other drugs for joints. In
addition, each participant provided information about
when he/she had used each drug: in the last 24 hours,
greater than 24 hours but less than 2 weeks ago, 2 to
less than 4 weeks ago, 4 weeks to less than 3 months
ago, or more than 3 months ago.
Pharmacological and supplement use follow-up
questionnaire
The Pharmacological and Supplement Use Follow-up
Questionnaire was used to discern additional details
concerning the participant’s specific medication use. Fol-
low-up questions addressed the drug dose; OTC versus
prescription drug; if the drug was taken as directed and
consistently; if more than one drug was being taken;
and if the drug was no longer being taken, and, if not,
why it was stopped.
Procedures
Participants were recruited from Temple University
Hospital’s Department of Orthopedics and informed of
the study’s purpose. Those who agreed to participate
read and signed the study compliance forms. Next, the
participant was interviewed by one of the coauthors
(SB) using the Demographic and Health History Ques-
tionnaire as well as Pharmacological and Supplement
Use Assessment Questionnaire in sequential order in a
private examination room. The interview had no time
limit, but the average interview took between 15 and 20
minutes to complete. Based on the responses to each of
the initial questionnaires, participants were then inter-
viewed by the same co-author using the appropriate fol-
low-up questionnaire(s).
Statistical analysis
Data analyses included descriptive statistics using the
SAS 9.2 (SAS Institute, Cary,N C )s t a t i s t i c a lp a c k a g e .
Items were analyzed with mean, standard deviation, fre-
quency and/or percentage statistics. Sampling error was
± 7.84%.
Logistic regressions were performed to predict 1) same
day dual-medication use, 2) participants that only used
self-guided recommendations compared to those that
only used professionally-guided recommendations, 3)
use of medication as directed, and 4) reporting a medi-
cation as ineffective or requiring a stronger medication.
Potential predictors were ethnicity, sex, obesity, age,
reporting multiple OA joints, and education. Models
were calculated with SPSS 20 (IBM Corporation,
Armonk, NY) and considered significant if the overall p-
value was ≤ 0.05. The sensitivity and specificity of signif-
icant models was calculated with Diagnostic Utility Sta-
tistics [10].
Two Fisher’s Exact Tests were performed in SAS 9.2
to further assess potential confounders for patients
reporting their medication as ineffective or requiring a
stronger medication. One test assessed the association
between participants reporting their medication as inef-
fective and not always using medication as directed. The
other test evaluated the association between participants
reporting their medication as ineffective and not always
using medication consistently. Fishers exact tests were
considered significant if the p-value was ≤ 0.05.
Results
Of the 162 participants, 151 participants had primary
complaints of knee OA (53% [n = 80] self-reported OA
in other joints), and 11 had hip OA (82% [n = 9] self-
reported OA in other joints). Kellgren-Lawrence scores
were distributed as follows: 1 (1.23%), 2 (21.60%), 3
(41.36%), and 4 (35.80%). Additional descriptive infor-
mation is provided in Table 1. Furthermore, Table 2
includes the overall number of reported medications
and supplements. Five participants reported not taking
any medications or supplements. Three of the five
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intra-articular injections only. Another participant that
reported no medications or supplements stated that she
was avoiding medication use because of an adverse
event with an intra-articular injection. The final partici-
pant reported no medication or supplement use but did
not provide a reason for doing so. These 5 participants
were excluded from the remainder of the analyses.
The type and source of pharmacological and supple-
ment use information is reported in Table 2. The most
common class of intervention was NSAIDs (particularly
n a p r o x e n[ 2 9 . 6 % ]a n di b u p r o f e n[ 2 4 . 1 % ] )f o l l o w e db y
other analgesics (i.e., prescription analgesics), acetamino-
phen, and nutritional supplements. Half of the partici-
pants reported using prescription medications only, while
approximately a quarter of the participants used OTC
medications and supplements only. Almost 20% of the
participants used both prescription and OTC medica-
tions and supplements. Most patients (55.6%) reported
only professionally-guided recommendations, 24.1% indi-
cated only self-guided recommendations, and 17.3%
reported professionally and self-guided recommendations
for their medication and supplement use. Results of the
logistic regression used to evaluate predictors (i.e., ethni-
city, sex, obesity, age, reporting multiple OA joints, and
education) of a participant only using self-guided recom-
mendations compared to only using professionally-
guided recommendations was not significant (p = 0.149).
Also reported in Table 2 is the pattern of medication
use information. Less than half of the participants were
always able to recall their medication dose, while the
balance was either unable or partially able to do so.
Twenty-nine percent of the participants reported never
or only sometimes using their medication and/or sup-
plement as directed, while the balance reported they
always took their medication and/or supplement as
directed. Results of the logistic regression used to evalu-
ate predictors (i.e., ethnicity,s e x ,o b e s i t y ,a g e ,r e p o r t i n g
multiple OA joints, and education) of a participant not
always using their medication as directed was not signif-
icant (p = 0.139). Approximately half of the participants
reported taking their medication and/or supplement
consistently for 2 weeks whereas the others did not.
Table 1 Study sample characteristics (n = 162)
Variable Distribution
n (%) or m ± sd
Female 108 (66.7%)
Ethnicity
African descent 118 (72.8%)
Caucasian 28 (17.3%)
Hispanic and/or Other 16 (9.9%)
Education
Less than High School 44 (27.2%)
High School (or Equivalent) 78 (48.2%)
Beyond High School 40 (24.7%)
Age (years) 59 ± 10
Body mass index (kg/m
2) 35.1 ± 7.6
m = mean, sd = standard deviation.
Table 2 Pharmacological and supplemental use among
osteoarthritis knee and hip patients
Type, source and pattern of use Frequency Percentage
Overall number of reported interventions*
Zero 5 3.1
One 92 56.8
Two 55 34.0
Three or More 10 6.2
Class of intervention‡
NSAID 106 65.4
Other analgesics 55 34.0
Acetaminophen 38 23.5
Nutritional supplement 11 06.8
Level of intervention‡
Rx user only 80 49.4
OTC user only 46 28.4
Rx and OTC user 31 19.1
Source of recommendation‡
PCP only 41 25.3
Self-guided only 39 24.1
Orthopedic only 28 17.3
PCP and self-guided 16 09.9
Multiple professional sources 12 07.4
Orthopaedic and self-guided 11 06.8
Other sources 10 06.2
Recall medication dose‡
All 76 46.9
None 53 32.7
Some 28 17.3
Medications used as directed‡
Always 110 67.9
Never 34 21.0
Sometimes 13 08.0
2 week consistent medication use‡
Always 88 54.3
Never 48 29.6
Sometimes 21 13.0
* Interventions = prescription or over-the-counter medication as well as
supplements.
‡ N = 157/162 participants whom reported using a pharmacological
intervention, 5 participants reported using none.
NSAID = non-steroidal anti-inflammatory drug, Rx = prescription, OTC = over-
the-counter, and PCP = primary care physician.
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medication and/or supplement users while 15 (9%) par-
ticipants were taking the combinations at the same time.
Dual-medication and/or supplement use pattern infor-
mation is represented in Table 3. The majority of parti-
cipants used multiple classes of medications at the same
time. Eighty-six percent of dual-use participants
reported using prescription medications only or both
prescription and OTC medications at the same time.
Results of the logistic regression to evaluate predictors
of an individual being a same day dual-medication user
were statistically significant. The Homer-Lemeshow
goodness-of-fit test showed a good model fit with the
data (p = 0.912). The overall accuracy of the model was
75.8% with a sensitivity of 44.4% and specificity of
77.7%. Participants reporting OA at multiple joints were
more likely to be same day dual-medication users (odds
ratio [95% confidence interval; CI] = 2.48 [1.03 to 5.96])
after controlling for covariates (i.e., ethnicity, sex, obe-
s i t y ,a g e ,a n de d u c a t i o n ) .I nc o n t r a s t ,p a r t i c i p a n t sw i t h
less than a high school education were 3.82 times less
likely to be same day dual-medication users (odds ratio
[95% CI] = 0.26 [0.08 to 0.83]) than participants with a
high school education or greater.
T h es o u r c eo fr e c o m m e n d a t i o no fs a m et i m ed u a l -
medication and/or supplementu s ei sr e p o r t e di nT a b l e
4. Two participants reported 2 distinct patterns of dual
use, resulting in fifteen participants reporting 17 dual-
use combinations. Of these 17 dual-use combinations,
11 (65%) were professionally-guided based recommenda-
tions (physician-physician), 5 (29%) were professional
and self-guided-based recommendations (physician-self),
and 1 (6%) was a self-guided-based recommendation
(self-self). Common combinations included NSAIDs plus
analgesics (e.g., acetaminophen, tramadol; 9 out of 17)
and medication plus supplement (e.g., calcium glucosa-
mine; 5 out of 17).
Table 5 describes several additional behaviors that
participants reported to manage joint symptoms.
Twenty-nine (18.5%) participants reported their medica-
tion as ineffective, required a stronger medication, or
used illegal drugs to manage their symptoms. Alterna-
tively, 15 (9.6%) participants sought an alternative
method to achieve symptom relief (i.e., emergency room
for symptom management, used other person’s prescrip-
tion medication, or used medication prescribed for an
alternative ailment). Overall, 28% of participants
reported their intervention as ineffective, sought an
alternative method to achieve symptom relief, or were
prescribed a stronger medication. Results of the logistic
regression used to evaluate predictors (i.e., ethnicity, sex,
obesity, age, reporting multiple OA joints, and educa-
tion) of a participant reporting their medication as inef-
fective or requiring a stronger medication was not
significant (p = 0.087). Conversely, Fisher’sE x a c tT e s t
revealed that participants who reported not always tak-
ing their medication consistently for 2 weeks were more
likely to report their medication as ineffective (24.6% of
participants) compared to participants always taking
their medication consistently for 2 weeks (10.2% of par-
ticipants; odds ratio [95% CI] = 2.87 [1.19 to 6.92], p =
0.010). No association was found between participants
reporting medication as ineffective or requiring stronger
medication and not always using medication as directed
(p = 0.153). Thirteen participants reported other reasons
for discontinuing their medication (e.g., no longer
needed the medication, physician concerns regarding
potential risks, patient fear of addiction, insurance
refused to cover medication).
Discussion
Although a majority of participants reported using pro-
fessionally-guided recommendations, over 40% reported
using at least one self-guided pharmacological and/or
supplement intervention to manage their knee OA joint
symptoms. Of the 15 participants who reported dual-use
at the same time, 11 were professionally-guided, 5 were
professional and self-guided, and 1 was solely self-
guided based recommendation. Even with the combina-
tions of professionally-guided, self-guided, and multiple
sources of recommendation almost 17% of participants
reported their intervention as ineffective or were pre-
scribed a stronger medication. The only variable asso-
ciated with participants reporting their intervention as
ineffective (or requiring stronger medication) was not
always taking their medication consistently for 2 weeks.
Our study revealed that nearly 20% of participants
tried prescription and OTC medications to manage their
joint symptoms. Among patients taking multiple
Table 3 Day and time patterns of multiple-medication
use among osteoarthritis knee and hip patients
Multiple-
medication use
Same day (n = 37) Same time (n = 15)
Frequency Percentage Frequency Percentage
Class of
intervention
Multiple-classes 30 81.1 14 93.3
NSAID only 5 13.5 0 0
Other 2 05.4 1 06.7
Level of
intervention
Rx and OTC user 15 40.5 5 33.3
Rx user only 13 35.1 8 53.3
OTC user only 9 24.3 2 13.3
NSAID = non-steroidal anti-inflammatory drug, Rx = prescription, and OTC =
over-the-counter.
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scription and OTC interventions. In Canada, 41% of
patients recruited from urban primary care practices (n
= 78 out of 190) reported using prescription medication
and self-care products to manage their joint symptoms
during one week [4]. It could not be determined if the
Canadian patients were taking their medication combi-
nations on the same day but this is likely since patients
were asked to recall their medication use only for the
week prior to the survey [4].
The overall combination of prescription and OTC
i n t e r v e n t i o n si no u rs t u d ym a yb el o w e rt h a ni nt h e
Canadian study [4] because they had fewer participants
consuming only prescription medications (11% Canada
versus 49% current study). The use of only OTC inter-
ventions was similar between studies (33% Canada ver-
sus 28% current study). The high prevalence of
prescription medication use in the current study is simi-
lar to a cohort study conducted in Pittsburgh, Pennsyl-
vania that had a high prevalence of prescription (54%)
a n dO T C( 6 3 % )m e d i c a t i o nu s ed u r i n ga3 0 - d a yp e r i o d
[3]. This study did not indicate whether participants
were patients were taking a combination of prescriptions
and OTC medications and supplements were included
as a different class of interventions. Participants in the
Pittsburgh study were requested to “bring in” their med-
ications to be recorded on a medication inventory form.
Based on these data, the authors reported that 70% of
Table 4 Source of recommendation of dual-medication or nutritional supplement use among osteoarthritis knee and
hip patients
Participant # Drug 1 Drug 2 Source of Recommendation
Drug 1 Drug 2
1 Indomethacin Acetaminophen PCP Self-guided
2 Diclofenac Tramadol Orthopedic Orthopedic
3 Acetaminophen Calcium Orthopedic Self-guided
4 Ibuprofen Calcium Self-guided Self-guided
4 Naproxen Calcium PCP Self-guided
5 Naproxen Glucosamine PCP PCP
6 Naproxen Acetaminophen + Codeine PCP PCP
7 Ibuprofen Acetaminophen + Oxycodone Self-guided PCP
8 Tramadol Acetaminophen + Codeine Orthopedic PCP
9 Naproxen Acetaminophen PCP PCP
10 Oxycodone Hydromorphone Psychiatrist Psychiatrist
11 Diclofenac Tramadol Orthopedic Orthopedic
12 Meloxicam Tramadol Orthopedic Orthopedic
12 Ibuprofen Tramadol Self-guided Orthopedic
13 Glucosamine Chondroitin Orthopedic Orthopedic
14 Ibuprofen Acetaminophen + Oxycodone PCP ER
15 Tramadol Acetaminophen + Oxycodone PCP PMC
Participants 4 and 12 had 2 distinct patterns of use.
PCP = primary care physician, Orthopedic = orthopedic surgeon, ER = emergency room physician, and PMC = pain management center.
Table 5 Additional behaviors among medication and supplement users (n = 157)
Behavior Distribution
n (%)
Reported Medication/Supplement As Ineffective or were Prescribed Stronger Dose 26 (16.6%)
Use of Illegal Drugs (e.g., marijuana) 3 (1.9%)
Use of Other Person’s Prescription Medication 3 (1.9%)
Use of Medication Prescribed for Other Ailments 7 (4.5%)
Received Medication from Emergency Room 5 (3.2%)
Adverse Events from Medications/Supplements 5 (3.2%)
Stopped Medication Because the Prescription Ran out 17 (10.8%)
Stopped Medication for Miscellaneous Reasons 13 (8.3%)
m = mean, sd = standard deviation.
Driban et al. BMC Musculoskeletal Disorders 2012, 13:47
http://www.biomedcentral.com/1471-2474/13/47
Page 6 of 8the participants were consuming prescription medica-
tions for OA symptom management. This is similar to
our overall prescription medication use (69%) which was
based on an interview-questionnaire format.
In the Pittsburgh study [3], among OTC medications,
NSAIDs (58%: including COX-2 selective inhibitors)
were the most commonly used drug class followed by
other analgesics (55.7%). Our findings, although not lim-
ited to just OTC medications, were similar with NSAIDs
being the most commonly used drug class utilized by
65% of participants followed by other analgesics (57%).
These findings contradict current guidelines and recom-
mendations that suggest acetaminophen should be the
first line of defense over NSAIDs [2,11]. However, it is
not known if the participants in our study had pre-
viously failed with acetaminophen treatment and there-
fore progressed to NSAIDs. Future research should
include assessments of whether NSAIDs are commonly
recommended after failure with other analgesics.
Approximately 23% of participants reported dual-use
in the same day, while 9% of participants reported dual-
use at the same time. While these data include OTC
and prescription medications, the findings are similar to
those reported by Albert et al [3] in which 23% of the
patients used prescription medications in 2 or more
classes. The extent to which the dual medication use
occurred within the same day is not reported. Partici-
pants were more likely to use multiple medications on
the same day if they reported that more than one joint
had OA or if they had a high school education or
greater. Future research should explore if patients are
taking more than one medication because they believe
each medication is for a particular joint or if one medi-
cation is only helpful for certain joints and not others.
Although dual-use is not necessarily bad or against cur-
rent guidelines and recommendations, four of five orga-
nizations currently offer no statement on dual-use
[2,12-14]. The American College of Rheumatology is the
only organization to offer a statement advocating dual-
use for the treatment of OA [11]. While future research
should evaluate medication dosage by using medication
inventory forms, the data from our study indicates that
the same-time dual-use combinations tend to be low-
risk combinations (e.g., medications with supplements,
NSAIDs with analgesics); however, recent research has
raised concerns about the safety of combining NSAIDs
with acetaminophen [15].
The current study identified several behaviors that
have not been well studied in past OA research and
may warrant further investigation. Thirteen (8%) partici-
pants reported using alternative methods to achieve
symptomatic relief (e.g., misusing a prescription medica-
tion or consuming marijuana). Similarly, 26 participants
reported stopping a medication because it was
ineffective or they were prescribed a stronger medica-
tion. Based on these two findings it may be hypothe-
sized that almost 1 in 5 patients in this cohort perceived
one of their interventions to be ineffective. Participants
that reported not taking medication consistently for 2
weeks were more likely to report their medication as
ineffective. While longitudinal studies may be required
to infer causality, it may be beneficial to suggest to
patients that they should try new medications consis-
tently (as prescribed) for at least 2 weeks. An additional
17 participants stopped taking their intervention because
their prescription “ran out”. We hypothesize that the
reasons for this may have been due to socioeconomic
status, access to healthcare, or effectiveness; but are yet
to be determined as this was not the focus of the cur-
rent study. These results highlight the need for clini-
cians to discuss with patients their satisfaction with
interventions and what they should do if they believe a
treatment is ineffective or their medication runs out.
The current study had several limitations. First was
the sample size, which resulted in a ± 7.84% error rate.
Another limitation of the study was that all participants
were recruited from one inner-city orthopedic practice,
narrowing the external validity of the study. The study
also relied solely on self-reporting of medication use,
which leaves the potential for misclassification of phar-
macological and supplemental interventions. The Phar-
macological and Supplement Use Assessment
Questionnaire used in this study may have reduced the
risk of misclassification because it provided a list of
common NSAIDs and other interventions. Self-reported
medication use was selected because of limitations
within the current health system, a desire to capture
over-the-counter medication use, and a preference to
include any patient entering the clinic compared to a
potentially biased sample of people that were willing to
return with their medication bottles. We hypothesize
that self-reporting was more likely to bias the results
towards less medication use and safer patterns of medi-
cation use. Ostensibly, our data may represent a conser-
vative reflection of how patients in an inner-city
orthopaedic clinic manage their symptoms. Future lar-
ger, multi-center, epidemiology studies should be pur-
sued. Although inclusion of medication inventory forms
may help gather more information about current medi-
cation uses, the current instruments helped evaluate the
behavior and influences on decisions concerning patient
medication use. More research is needed to evaluate
patient motives and alternative treatment strategies pur-
sued through nontraditional mechanisms.
Conclusions
In conclusion, in a small cohort of inner-city orthopae-
dic patients trying to manage their joint symptoms a
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OTC medications, were unable to recall their medica-
tion dose, and reported not taking their medication as
directed. Furthermore, participants who reported never
taking their medication consistently for 2 weeks were
more likely to report their medication as ineffective.
Some patients stopped taking their medications because
their prescription ran out, sought additional sympto-
matic relief by taking multiple medications at the same
time, and reported inappropriate behaviors to achieve
symptomatic relief. Almost one in four patients reported
taking multiple medications or supplements during a
day to manage their symptoms. Patients reporting OA
at multiple joints and a higher education were more
likely to consume multiple interventions during a day to
manage their symptoms. Fortunately, combinations of
multiple medications at the same time appear to be low
risk (e.g., acetaminophen with NSAIDs). Based on this
study, it may be important for clinicians to discuss how
to manage multiple joint symptoms, the importance of
taking a medication as prescribed, and what they should
do if they believe a treatment is ineffective or their med-
ication runs out.
Additional material
Additional file 1: Demographic and Health History Questionnaire.
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